Keratoconjunctivitis Sicca (Dry Eye) Therapeutics Pipeline Report, H1 2017 - Review of 40 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H1 2017" report to their offering.

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 21, 11, 1, 19, 5 and 1 respectively.

Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Keratoconjunctivitis Sicca (Dry Eye) - Overview
  3. Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
  1. Aldeyra Therapeutics Inc
  2. Allergan Plc
  3. Ascendia Pharmaceuticals LLC
  4. BioLineRx Ltd
  5. Cambium Medical Technologies LLC
  6. Chong Kun Dang Pharmaceutical Corp
  7. Dompe Farmaceutici SpA
  8. Elasmogen Ltd
  9. HanAll Biopharma Co Ltd
  10. Herantis Pharma Plc
  11. Huons Co Ltd
  12. InSite Vision Inc
  13. Kala Pharmaceuticals Inc
  14. KPI Therapeutics Inc
  15. Kukje Pharmaceutical Industry Co Ltd
  16. Laboratoires Thea SA
  17. Lipicard Technologies Ltd
  18. Merck & Co Inc
  19. Mimetogen Pharmaceuticals Inc
  20. Mitotech SA
  21. Nanomerics Ltd
  22. Nemus Bioscience Inc
  23. Neuroptis Biotech
  24. Novaliq GmbH
  25. Ocular Therapeutix Inc
  26. Oculis ehf
  27. OncoNOx ApS
  28. Otsuka Holdings Co Ltd
  29. Seikagaku Corp
  30. Shire Plc
  31. Sun Pharmaceutical Industries Ltd
  32. TearSolutions LLC
  33. TopiVert Ltd
  34. Vanda Pharmaceuticals Inc
  35. Xigen SA

For more information about this report visit http://www.researchandmarkets.com/research/n2v5nb/keratoconjunctivit

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical, Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical, Optical Disorders Drugs